Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
The in vivoanticancer efficacy of nanoparticle-mediated drug delivery depends on the association between the drug and its carrier. Here, the authors use FRET to show that the drug hydrophobicity, and miscibility with the carrier, influence nanoparticle accumulation in murine tumour models.
Guardado en:
Autores principales: | Yiming Zhao, François Fay, Sjoerd Hak, Jose Manuel Perez-Aguilar, Brenda L. Sanchez-Gaytan, Brandon Goode, Raphaël Duivenvoorden, Catharina de Lange Davies, Astrid Bjørkøy, Harel Weinstein, Zahi A. Fayad, Carlos Pérez-Medina, Willem J. M. Mulder |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d90fceee65ae4c4ca9f5fa1e73acfa06 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
por: Carlos Pérez-Medina, et al.
Publicado: (2016) -
Ormeloxifene nanotherapy for cervical cancer treatment
por: Chauhan N, et al.
Publicado: (2019) -
Molecular targets in arthritis and recent trends in nanotherapy
por: Roy K, et al.
Publicado: (2015) -
Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers
por: Yang Liu, et al.
Publicado: (2017) -
Reduced graphene oxide–silver nanoparticle nanocomposite: a potential anticancer nanotherapy
por: Gurunathan S, et al.
Publicado: (2015)